{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:02:37Z","timestamp":1790136157299,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Despite cefoxitin's in vitro resistance to hydrolysis by extended-spectrum beta-lactamases (ESBL), treatment of ESBL-producing\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (KP) infections with cefoxitin remains controversial. The aim of our study was to compare the clinical efficacy of cefoxitin as definitive antibiotic therapy for patients with ESBL-KP bacteremia in intensive care unit, versus carbapenem therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included all patients with monomicrobial bacteremia hospitalized in intensive care unit between January 2013 and January 2023 at the University Hospital of Guadeloupe. The primary outcome was the 30-day clinical success defined as a composite endpoint: 30-day survival, absence of relapse and no change of antibiotic therapy. Cox regression including a propensity score (PS) and PS-based matched analysis were performed for endpoint analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 110 patients with bloodstream infections were enrolled. Sixty-three patients (57%) received definitive antibiotic therapy with cefoxitin, while forty-seven (43%) were treated with carbapenems. 30-day clinical success was not significantly different between patients treated with cefoxitin (57%) and carbapenems (53%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.823). PS-adjusted and PS-matched analysis confirmed these findings. Change of definitive antibiotic therapy was more frequent in the cefoxitin group (17% vs. 0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). No significant differences were observed for the other secondary endpoints. The acquisition of carbapenem-resistant\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      was significantly higher in patients receiving carbapenem therapy (5% vs. 23%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our results suggest that cefoxitin as definitive antibiotic therapy could be a therapeutic option for some ESBL-KP bacteremia, sparing carbapenems and reducing the selection of carbapenem-resistant\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      strains.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-023-04712-2","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T03:02:26Z","timestamp":1698807746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cefoxitin versus carbapenems as definitive treatment for extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Tanguy","family":"Dequidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvaine","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Nacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Breurec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Carles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Camous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Tressieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-David","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"4712_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini A, H\u00f6gberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19:56\u201366.","journal-title":"Lancet Infect Dis"},{"key":"4712_CR2","unstructured":"Surveillance de la consommation des antibiotiques et des r\u00e9sistances bact\u00e9riennes en \u00e9tablissement de sant\u00e9. Mission Spares. R\u00e9sultats synth\u00e9tiques, 2021."},{"key":"4712_CR3","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/jac\/dks301","volume":"67","author":"KZ Vardakas","year":"2012","unstructured":"Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793\u2013803.","journal-title":"J Antimicrob Chemother"},{"key":"4712_CR4","doi-asserted-by":"crossref","unstructured":"van\u00a0Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2016;8:460\u20139.","DOI":"10.1080\/21505594.2016.1222343"},{"key":"4712_CR5","doi-asserted-by":"crossref","unstructured":"Jacoby GA, Carreras I. Activities of 3-Lactam Antibiotics against Escherichia coli strains producing extended-spectrum 13-lactamases. Antimicrob Agents Chemother. 1990;34.","DOI":"10.1128\/AAC.34.5.858"},{"key":"4712_CR6","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1128\/AAC.02509-14","volume":"58","author":"H Guet-Revillet","year":"2014","unstructured":"Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, et al. Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2014;58:4899\u2013901.","journal-title":"Antimicrob Agents Chemother"},{"key":"4712_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","volume":"48","author":"F Caron","year":"2018","unstructured":"Caron F, Galperine T, Flateau C, Azria R, Bonacorsi S, Bruy\u00e8re F, et al. Practice guidelines for the management of adult community-acquired urinary tract infections. M\u00e9decine Mal Infect. 2018;48:327\u201358.","journal-title":"M\u00e9decine Mal Infect"},{"key":"4712_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ijantimicag.2018.01.008","volume":"51","author":"E Demonchy","year":"2018","unstructured":"Demonchy E, Courjon J, Ughetto E, Durand M, Risso K, Garraffo R, et al. Cefoxitin-based antibiotic therapy for extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study. Int J Antimicrob Agents. 2018;51:836\u201341.","journal-title":"Int J Antimicrob Agents"},{"key":"4712_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.medmal.2016.04.008","volume":"46","author":"A Mambie","year":"2016","unstructured":"Mambie A, Vuotto F, Poitrenaud D, Weyrich P, Cannesson O, Dessein R, et al. Cefoxitin: an alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Med Mal Infect. 2016;46:215\u20139.","journal-title":"Med Mal Infect"},{"key":"4712_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12879-016-1770-1","volume":"16","author":"T Fukuchi","year":"2016","unstructured":"Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. BMC Infect Dis. 2016;16:427.","journal-title":"BMC Infect Dis"},{"key":"4712_CR11","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1128\/AAC.00701-15","volume":"59","author":"Y Matsumura","year":"2015","unstructured":"Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, et al. Multicenter retrospective study of Cefmetazole and Flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015;59:5107\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"4712_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10096-019-03701-0","volume":"39","author":"O Senard","year":"2020","unstructured":"Senard O, Lafaurie M, Lesprit P, Nguyen Y, Lescure X, Therby A, et al. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2020;39:121\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"4712_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/jac\/dkl381","volume":"58","author":"CH Lee","year":"2006","unstructured":"Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother. 2006;58:1074\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"4712_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/infdis\/159.5.1005","volume":"159","author":"B Pangon","year":"1989","unstructured":"Pangon B, Bizet C, Bur\u00e9 A, Pichon F, Philippon A, Regnier B, et al. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis. 1989;159:1005\u20136.","journal-title":"J Infect Dis"},{"key":"4712_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3109\/23744235.2015.1062133","volume":"47","author":"S Kern\u00e9is","year":"2015","unstructured":"Kern\u00e9is S, Valade S, Geri G, Compain F, Lavollay M, Rostane H, et al. Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Dis. 2015;47:789\u201395.","journal-title":"Infect Dis"},{"key":"4712_CR16","doi-asserted-by":"crossref","unstructured":"Arnaud I, Maugat S, Jarlier V, Astagneau P, National Early Warning, Investigation and Surveillance of Healthcare-Associated Infections Network (RAISIN)\/multidrug resistance study group. Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2015;20.","DOI":"10.2807\/1560-7917.ES.2015.20.36.30014"},{"key":"4712_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13054-021-03660-z","volume":"25","author":"C Le Terrier","year":"2021","unstructured":"Le Terrier C, Vinetti M, Bonjean P, Richard R, Jarrige B, Pons B, et al. Impact of a restrictive antibiotic policy on the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an endemic region: a before-and-after, propensity-matched cohort study in a Caribbean intensive care unit. Crit Care. 2021;25:261.","journal-title":"Crit Care"},{"key":"4712_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"4712_CR19","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Le Gall","year":"1993","unstructured":"Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study. JAMA. 1993;270:2957\u201363.","journal-title":"JAMA"},{"key":"4712_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"4712_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/SHK.0b013e318182f98f","volume":"31","author":"JY Rhee","year":"2009","unstructured":"Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS, Chung DR, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the pitt bacteremia score and the acute physiology and chronic health evaluation II scoring systems. Shock. 2009;31:146\u201350.","journal-title":"Shock"},{"key":"4712_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801.","journal-title":"JAMA"},{"key":"4712_CR23","doi-asserted-by":"crossref","unstructured":"Kahlmeter G, EUCAST Steering Committee. EUCAST proposes to change the definition and usefulness of the susceptibility category \u00ab\u00a0Intermediate\u00a0\u00bb. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2017;23:894\u20115.","DOI":"10.1016\/j.cmi.2017.08.015"},{"key":"4712_CR24","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, N.J: L. Erlbaum; 1988."},{"key":"4712_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13613-022-01059-9","volume":"12","author":"P Chabert","year":"2022","unstructured":"Chabert P, Provoost J, Cohen S, Dupieux-Chabert C, Bitker L, Ferry T, et al. Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study. Ann Intensive Care. 2022;12:90.","journal-title":"Ann Intensive Care"},{"key":"4712_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/1471-2334-12-206","volume":"12","author":"CC Yang","year":"2012","unstructured":"Yang CC, Li SH, Chuang FR, Chen CH, Lee CH, Chen JB, et al. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniaein patients on maintenance hemodialysis. BMC Infect Dis. 2012;12:206.","journal-title":"BMC Infect Dis"},{"key":"4712_CR27","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ijantimicag.2015.07.020","volume":"46","author":"CH Lee","year":"2015","unstructured":"Lee CH, Su LH, Chen FJ, Tang YF, Li CC, Chien CC, et al. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study. Int J Antimicrob Agents. 2015;46:610\u20135.","journal-title":"Int J Antimicrob Agents"},{"key":"4712_CR28","doi-asserted-by":"crossref","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the T Treatment of Antimicrobial Resistant Gram-Negative P Infections.","DOI":"10.1093\/cid\/ciad428"},{"key":"4712_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12879-023-08018-0","volume":"23","author":"JF Garc\u00eda-Rodr\u00edguez","year":"2023","unstructured":"Garc\u00eda-Rodr\u00edguez JF, Mari\u00f1o-Callejo A. The factors associated with the trend in incidence of Bacteraemia and associated mortality over 30 years. BMC Infect Dis. 2023;23:69.","journal-title":"BMC Infect Dis"},{"key":"4712_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijregi.2023.01.005","volume":"6","author":"AM Peri","year":"2023","unstructured":"Peri AM, Calabretta D, Bozzi G, Migliorino GM, Bramati S, Gori A, et al. Retrospective analysis of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacterales: the challenge of healthcare-associated infections. IJID Reg. 2023;6:167\u201370.","journal-title":"IJID Reg"},{"key":"4712_CR31","unstructured":"Ang SH, Periyasamy P, Shah SA, Ramli R, Lau CL. Risk factors for complications and survival outcomes of Klebsiella pneumoniae Bacteraemia in Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia. 2022;77."},{"key":"4712_CR32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1128\/AAC.40.2.342","volume":"40","author":"L Mart\u00ednez-Mart\u00ednez","year":"1996","unstructured":"Mart\u00ednez-Mart\u00ednez L, Hern\u00e1ndez-All\u00e9s S, Albert\u00ed S, Tom\u00e1s JM, Benedi VJ, Jacoby GA. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother f\u00e9vr. 1996;40:342\u20138.","journal-title":"Antimicrob Agents Chemother f\u00e9vr"},{"key":"4712_CR33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1128\/AAC.43.4.937","volume":"43","author":"S Hern\u00e1ndez-All\u00e9s","year":"1999","unstructured":"Hern\u00e1ndez-All\u00e9s S, Bened\u00ed VJ, Mart\u00ednez-Mart\u00ednez L, Pascual \u00c1, Aguilar A, Tom\u00e1s JM, et al. Development of resistance during antimicrobial therapy caused by insertion sequence interruption of porin genes. Antimicrob Agents Chemother. 1999;43:937\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"4712_CR34","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1128\/AAC.01275-10","volume":"55","author":"YK Tsai","year":"2011","unstructured":"Tsai YK, Fung CP, Lin JC, Chen JH, Chang FY, Chen TL, et al. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother. 2011;55:1485\u201393.","journal-title":"Antimicrob Agents Chemother"},{"key":"4712_CR35","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s10096-021-04165-x","volume":"40","author":"B Pilmis","year":"2021","unstructured":"Pilmis B, Mizrahi A, Mory C, Le Monnier A, El Helali N. How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection? Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2021;40:1393\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04712-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T03:03:23Z","timestamp":1698807803000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04712-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4712"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04712-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3318194\/v1","asserted-by":"object"}]},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures were in accordance with the 1964 Declaration of Helsinki and its later amendments. Participants received an information notice mentioning their participation to the study and giving the possibility of objecting, according to French legislation. The study was approved by Ethical Committee of the UHG (N\u00b0A105_24\/04\/2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}